专利号:US-7169589-B2 优先权日:2000-07-28 标题 :Silicatein-mediated synthesis of amorphous silicates and siloxanes and use thereof 发明人:MUELLER WERNER E G; SCHROEDER HEINZ C; LORENZ BERND; KRASKO ANATOLI 权利人:MUELLER WERNER E G; SCHROEDER HEINZ C; LORENZ BERND; KRASKO ANATOLI 摘要:Silicatein is an enzyme of silicate-forming organisms used for the synthesis of their silicate scaffold. The present invention relates to the use of highly-expressed and highly active recombinant silicatein, silicatein isolated from natural sources after gene induction as well as silicatein-fusion proteins for the synthesis of amorphous silicon dioxide (silicic acids and silicates), siloxanes as well as modification of these compounds and their technical use.
专利号:US-6451543-B1 优先权日:1998-08-31 标题:Lipid matrix-assisted chemical ligation and synthesis of membrane polypeptides 发明人:KOCHENDOERFER GERD G; HUNTER CHRISTIE L; KENT STEPHEN B H; BOTTI PAOLO 权利人:GRYPHON SCIENCES 摘要:The present invention relates to methods and compositions for lipid matrix-assisted chemical ligation and synthesis of membrane polypeptides that are incorporated in a lipid matrix. The invention is exemplified in production of a prefolded membrane polypeptide embedded within a lipid matrix via stepwise chemoselective chemical ligation of unprotected peptide segments, where at least one peptide segment is embedded in a lipid matrix. Any chemoselective reaction chemistry amenable for ligation of unprotected peptide segments can be employed. Suitable lipid matrices include liposomes, micelles, cell membrane patches and optically isotropic cubic lipidic phase matrices. Prefolded synthetic and semi-synthetic membrane polypeptides synthesized according to the methods and compositions of the invention also permit site-specific incorporation of one or more detectable moieties, such as a chromophore, which can be conveniently introduced during synthesis. The methods and compositions of the invention have multiple uses. For example, they can be used to assay ligand binding to membrane polypeptides and domains comprising a receptor, and thus are extremely useful for structure/function studies, drug screening/selection/design, and diagnostics and the like, including high-throughput applications. The methods and compositions of the invention are particularly suited for FRET analyses of previously inaccessible membrane polypeptides.
专利号:US-6548276-B2 优先权日:2000-09-06 标题:Enhanced in vitro synthesis of active proteins containing disulfide bonds 发明人:SWARTZ JAMES ROBERT; KIM DONG-MYUNG 权利人:UNIV LELAND STANFORD JUNIOR 摘要:Compositions and methods are provided for the enhanced in vitro synthesis of polypeptides containing disulfide bonds. In order to improve the performance of in vitro protein synthesis reactions, pre-treatment and redox buffering of the reaction mix is performed in order to optimize the redox potential. Exogenous enzymes that enhance protein folding and disulfide bond formation may also be added to the reaction.
专利号:US-7871794-B2 优先权日:2007-01-18 标 题:Enhanced cell-free synthesis of active proteins containing disulfide bonds 发明人:KNAPP KURTIS G; SWARTZ JAMES ROBERT 权利人:UNIV LELAND STANFORD JUNIOR 摘要:Compositions and methods are provided for the enhanced in vitro synthesis of active polypeptides containing disulfide bonds. In certain embodiments of the invention, the reaction mix includes a biological extract derived from a bacterial cell in which the glutathione reductase gene has been inactivated, which is pre-treated with a low concentration of a sulfhydryl inactivating agent.
专利号:US-5565606-A 优先权日:1986-10-21 标 题:Synthesis of peptide aminoalkylamides and peptide hydrazides by the solid-phase method 发明人:BREIPHOL GERHARD; KNOLLE JOCHEN 权利人:HOECHST AG 摘要:The invention relates to compounds of the formula I in which A denotes hydrogen or an amino protective group, B denotes one or more amino acids, X denotes alkylene or aralkylene, Y1, Y2, Y3 and Y4 are identical or different and denote hydrogen, methyl, methoxy or nitro, V denotes hydrogen or a carboxyl protective group, W denotes -[CH2]n- or -O-[CH2]n-, m denotes 0 or 1, n denotes 0 to 6, and p denotes 0 to 5, to a process for their preparation. The compounds of formula I are useful as linkage agents or anchor groups in the solid-phase synthesis of peptide aminoalkylamides and peptide hydrazides.
专利号:US-2002022022-A1 优先权日:2000-05-19 标题 :Inhibition of cell proliferation and matrix synthesis by antioxidants and NAD(P)H oxidase inhibitors 发明人:SHI YI; ZALEWSKI ANDREW 摘要:The present invention is directed to a method for the prophylactic and therapeutic treatment of diseases or disorders associated with the abnormal proliferation and extracellular matrix synthesis of smooth muscle cells (SMC) and fibroblasts due to activation of NAD(P)H and/or increased ROS generation. The method involves the administration of an NAD(P)H oxidase inhibitor(s) and/or antioxidant(s) to a mammal in an amount sufficient to treat the disease or disorder prophylactically or therapeutically. The NAD(P)H oxidase inhibitor inhibits the synthesis or translocation of NAD(P)H subunits, thereby blocking the generation of intracellular reactive oxygen species (ROS) and thus the proliferation and extracellular matrix synthesis of SMC and fibroblasts. Similarly, the administration of antioxidants blocks the generation of intracellular ROS, thereby inhibiting SMC and fibroblast proliferation and extracellular matrix synthesis. In addition to the prevention and treatment of vascular disease, such as atherosclerosis, graft disease, and restenosis, NAD(P)H oxidase inhibitors and antioxidants may be useful for the prevention and treatment of other conditions by decreasing cell proliferation and extracellular matrix synthesis associated therewith. These conditions include arthritis, keloid formation, cancer, tissue and organ fibrosis, and complications related to organ transplantation, metabolic syndrome, and radiation therapy.
1: Robert S, Wagner BK, Boulanger M, Richer M. Aprotinin. Ann Pharmacother. 1996 Apr;30(4):372-80. doi: 10.1177/106002809603000410. 42(4):81-91. doi: 10.1097/00004311-200404240-00009. 55(4):1033-41. doi: 10.1016/0003-4975(93)90149-c. 22(1):121-7. doi: 10.1097/ACO.0b013e32831c833f. 4(2):151-60. doi: 10.1586/14779072.4.2.151. 70 Suppl 1:46-9, e17. doi: 10.1111/anae.12907. 73(6):734-7. doi: 10.1093/bja/73.6.734. 49(6):954-83. doi: 10.2165/00003495-199549060-00008. 57(2):233-60. doi: 10.2165/00003495-199957020-00015. 105(4):949-62. doi: 10.1213/01.ane.0000281936.04102.9f. 119(11):631-46. friend or foe? A review of recent medical literature. Eur J Anaesthesiol. 2007 Jan;24(1):6-14. doi: 10.1017/S0265021506001955. Epub 2006 Nov 14. 13(3):16-23. 28(1):112-24. doi: 10.1592/phco.28.1.112. 102(4):757-8; author reply 758. doi: 10.3171/jns.2005.102.4.0757. 1(1):55-69. 36(2):97-102. doi: 10.1016/j.accpm.2017.02.001. Epub 2017 Feb 13. 18(1):21-41. doi: 10.2165/00002018-199818010-00003. 87(5):1129-36. doi: 10.2106/JBJS.D.02240. 18(4 Suppl):24S-28S. doi: 10.1053/j.jvca.2004.02.001.
合成参考文献
参考文献:10.1177/0267659111416877 摘要:Klugman D, Donofrio MT, Zurakowski D, Jonas RA. Postoperative complications following the Fontan procedure: the role of aprotinin. Perfusion. 2011 Nov;26(6):529–35. doi: 10.1177/0267659111416877. 参考文献:10.1074/jbc.m111.257527 摘要:Su Y, Miller TN, Navaneetham D, Schoonmaker RT, Sinha D, Walsh PN. The Role of Factor XIa (FXIa) Catalytic Domain Exosite Residues in Substrate Catalysis and Inhibition by the Kunitz Protease Inhibitor Domain of Protease Nexin 2. Journal of Biological Chemistry. 2011 Sep;286(36):31904–14. doi: 10.1074/jbc.m111.257527.